Abl (H396P), active

Background Information:

The Abl tyrosine kinase inhibitor STI571 (Gleevec™) is an effective therapy for stable-phase chronic myeloid leukemia patients. Many patients responding to STI571 later relapse, due to a reactivation of Bcr-Abl activity. In certain cases this appears to correlate with the presence of the H396P mutation, which confers resistance to drug binding due to steric interference. (Corbin AS. et al, Blood, (2002); 101:4611-4614 and La Rosee P. et al, Cancer Research; 62:7149-7153).

Target Class:

Kinase

Family:

TK

Sub Family:

Protein Tyrosine

Protein Name:

Abl

Protein Aliases:

Abelson murine leukemia viral oncogene homolog 1|Abelson tyrosine-protein kinase 1|Proto-oncogene c-Abl|p150

Accession Number:

U07563

UniProt Number:

P00519

Gene Name:

ABL1

Gene ID:

25

Gene Aliases:

JTK7|c-ABL|p150

Target Species:

Human